ABK Biomedical, Inc. e phatlalalitse mokuli oa pele ea ileng a phekoloa thutong ea ABK ea First-in-Human ka Eye90 microspheres™, sesebelisoa sa Y90 radioembolization bakeng sa phekolo ea kankere ea sebete. Boithuto bona bo etsoa ka tšebelisano le Sepetlele sa Auckland Research Unit, New Zealand.
Boithuto bo lebelletsoeng, bo nang le setsi se le seng, bo bulehileng bo hlahloba tšireletseho le katleho ea Eye90 microspheres ho bakuli ba nang le kankere e sa tsitsang ea hepatocellular carcinoma (HCC) kapa metastatic colorectal cancer (mCRC). Bakuli ba tla fumana phekolo e le 'ngoe ea Eye90 microspheres radioembolization ka maeto a morao-rao bakeng sa selemo se le seng ho hlahloba polokeho, katleho le boleng ba mehato ea bophelo.
Eye90 microspheres ke radiopaque glass microspheres tse bonahalang litšoantšong tsa x-ray le Computed Tomography (CT) 'me li na le Yttrium 90 (Y90) radiotherapeutic element. Y90 radioembolization, brachytherapy ea lehae, hajoale e sebelisoa ho alafa lihlahala tse kotsi tsa sebete. Kankere ea mantlha ea sebete ke mofetše oa botšelela o fumanoeng ka ho fetesisa ebile ke sesosa sa boraro se bakang lefu la mofetše lefatšeng ka bophara, 'me ho na le linyeoe tse ncha tse ka bang 906,000 selemo le selemo. HCC ke mofetše o atileng haholo oa sebete o nang le 75% -85% ea linyeoe tsohle tsa mofetše oa sebete 1 le bakuli ba bangata ba fumanoeng ba e-na le lefu le sa tsitsang. Kankere ea Colorectal (CRC) ke kankere ea boraro e fumanoeng ka ho fetisisa ea kankere2, hoo e ka bang 22% ea CRCs e teng e le mCRC ha e hlahlojoa qalong, 'me hoo e ka bang 70% ea bakuli ba tla qetella ba e-na le metastatic relapse.3
Mike Mangano, Mopresidente le CEO oa ABK Biomedical, o itse, "Re thabetse hore tšebelisano ea rona ea kliniki le Dr. Andrew Holden le Sepetlele sa Auckland, NZ, e fihletse ketsahalo ena ea bohlokoa. Re lumela hore li-microspheres tsa Eye90 li na le monyetla oa ho ntšetsa pele kalafo ea radioembolization ea Y90 nakong e ncha ea liphetho tse ntlafalitsoeng tsa bakuli. Ka ho khetheha, re lebelletse ho ithuta tsoelo-pele ea bohlokoa ea tekheniki eo Eye90 microspheres e fanang ka eona ho feta lisebelisoa tse tloaelehileng tsa Y90 radioembolization. Tsena li kenyelletsa sistimi ea pelehi e tsoetseng pele e lumellang taolo ea tsamaiso ea lingaka, pono e lebisitsoeng ho tumor, le bokhoni ba data ea x-ray-based imaging bakeng sa qeto e phahameng, CT-based, Eye90 microspheres precision dosimetry™". Dr. Robert Abraham, Mookameli oa Bongaka le Co-mothehi oa ABK Biomedical o itse, "E bile leeto le tsotehang la ho nka k'hamphani ho tloha khopolong ho ea ho phekolo ea mokuli. Re cheseha ebile re na le tšepo ka bokamoso ba ABK le Eye90 microspheres. "
Andrew Holden, MD, MBChB, FRANZCR, EBIR, ONZM, mofuputsi ea ka sehloohong oa thuto, o itse, "Re motlotlo ho ba ba pele ba ho phekola bakuli ka theknoloji ena e tsoetseng pele le ho etella pele thuto ena ea bohlokoa ea kliniki ho hlahloba theknoloji ena e ncha. Ho na le palo e ntseng e eketseha ea lithuto tsa radioembolization tse hatisitsoeng tsa Y90 tse bontšang katleho ea bongaka ho bakuli ba khethiloeng ka nepo. Re chesehela ho lekola hore na li-microspheres tsa Eye90, ka sistimi ea eona ea pelehi le litšoaneleho tse tsoetseng pele tsa litšoantšo li ka ama sephetho sa Y90 kalafong ea bakuli ba HCC le lihlahala tsa sebete tsa mCRC.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients with unresectable hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC).
- announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers.
- HCC is the most common primary liver cancer comprising 75%-85% of all primary liver cancer cases 1 with the majority of patients diagnosed .
